Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...

By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with ...

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

Valneva (VALN) stock in focus as the FDA suspends its chikungunya vaccine Ixchiq due to safety issues, including deaths. Read ...

Center for Biologics Evaluation and Research (CBER) has suspended the biologics license for Valneva’s Ixchiq (Chikungunya ...

On August 25, 2025, Valneva announced that the FDA suspended the license for its chikungunya vaccine, IXCHIQ®, in the U.S. due to four new reports of serious adverse events. This suspension requires ...

US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

Valneva shares dropped after it said it will no longer be able to sell its chikungunya vaccine in the U.S. after reports linked the vaccine to adverse effects. Shares trading in New York were nearly ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...